DaVita number of employees

DaVita reported 78,000 employees at December 31, 2025 in its latest annual report, up 2,000 (2.6%) on the year before. That compares with 69,000 at December 31, 2021. Revenue per employee was $174,911.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	78,000	+2,000 (2.6%)	$174,911	10-K, filed February 11, 2026
December 31, 2024	76,000	+6,000 (8.6%)	$168,626	10-K, filed February 13, 2025
December 31, 2023	70,000	+0 (0.0%)	$173,431	10-K, filed February 14, 2024
December 31, 2022	70,000	+1,000 (1.4%)	$165,856	10-K, filed February 22, 2023
December 31, 2021	69,000	—	$168,388	10-K, filed February 11, 2022

What the annual reports say

As of December 31, 2025, we employed approximately 78,000 teammates, including our international teammates, with approximately 72% of our teammates located within the U.S. 2025 annual report
As of December 31, 2024, we employed approximately 76,000 teammates, including our international teammates, with approximately 75% of our teammates located within the U.S. 2024 annual report
As of December 31, 2023, we employed approximately 70,000 teammates, including our international teammates. 2023 annual report
As of December 31, 2022, we employed approximately 70,000 teammates, including our international teammates. 2022 annual report
As of December 31, 2021, we employed approximately 69,000 teammates, including our international teammates. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: BTSG vs DVA DGX vs DVA

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from DaVita's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to DaVita.